Bordetella bronchiseptica in Dogs and Cats: Kennel Cough Pathogenesis, Diagnosis, and Control

Etiology and Taxonomy

Bordetella bronchiseptica is a Gram-negative, aerobic, motile coccobacillus belonging to the family Alcaligenaceae. The organism is a primary bacterial agent of the canine infectious respiratory disease complex (CIRDC), commonly termed kennel cough, and is also implicated in feline upper respiratory tract infections (URTIs) [1]. B. bronchiseptica is closely related to Bordetella pertussis and Bordetella parapertussis, sharing virulence determinants such as filamentous hemagglutinin, pertactin, and tracheal cytotoxin. The bacterium expresses peritrichous flagella, and flagellin typing has been used to differentiate strains originating from different host species, including dogs, cats, and swine [2]. This host tropism is relevant for understanding cross-species transmission and zoonotic potential, particularly in immunocompromised human populations [3].

Epidemiology and Transmission

B. bronchiseptica is enzootic in many canine and feline populations, with higher prevalence in crowded environments such as kennels, shelters, and multi-cat households. Transmission occurs via aerosolized respiratory secretions, direct contact, and fomites. The bacterium can survive for weeks in the environment under cool, moist conditions. In a molecular epidemiologic study of feline bordetellosis in two animal shelters in California, USA, Foley et al. [4] demonstrated that B. bronchiseptica infection was associated with young age, stress, and co-infection with other respiratory pathogens such as feline herpesvirus-1 and feline calicivirus. The prevalence in shelter cats can exceed 25% during outbreaks. In dogs, B. bronchiseptica is a core component of the CIRDC, often acting synergistically with canine parainfluenza virus and canine adenovirus type 2.

Bordetella bronchiseptica Kennel Cough Dogs Cats Diagnosis: Clinical Signs and Pathology

Clinical Signs in Dogs

In dogs, B. bronchiseptica infection typically presents as an acute, self-limiting tracheobronchitis. The hallmark clinical sign is a paroxysmal, dry, honking cough that may be elicited by tracheal palpation. Affected dogs remain bright and alert with normal appetite in uncomplicated cases. Nasal discharge, ocular discharge, and mild fever may be present. In puppies or immunocompromised animals, bronchopneumonia can develop, characterized by productive cough, dyspnea, lethargy, and anorexia.

Clinical Signs in Cats

Feline bordetellosis ranges from subclinical carriage to severe bronchopneumonia. Garbal et al. [1] reported that B. bronchiseptica was isolated from domestic cats with URTIs, with clinical signs including sneezing, serous to mucopurulent nasal discharge, conjunctivitis, and fever. Kittens are more susceptible to severe disease, which may manifest as pneumonia with tachypnea, cyanosis, and death. Co-infection with feline calicivirus or feline herpesvirus-1 exacerbates clinical severity.

Pathology

Gross pathological findings in dogs and cats include hyperemia of the tracheal and bronchial mucosa, with a variable amount of mucopurulent exudate. Histologically, the organism adheres to ciliated respiratory epithelial cells, causing ciliostasis, epithelial necrosis, and an influx of neutrophils and macrophages. The tracheal cytotoxin produced by B. bronchiseptica inhibits ciliary function and damages epithelial cells, facilitating secondary bacterial invasion. In severe cases, bronchopneumonia with suppurative exudate in alveoli and bronchioles is observed.

Pathogenesis and Virulence Factors

B. bronchiseptica employs a type III secretion system (T3SS) to inject effector proteins into host cells, modulating the immune response. The bacterium produces several adhesins, including filamentous hemagglutinin (FHA), pertactin, and fimbriae, which mediate attachment to ciliated respiratory epithelium. The BvgAS two-component regulatory system controls the expression of virulence factors in response to environmental conditions. At 37 degrees Celsius, the Bvg+ phase is activated, promoting expression of adhesins and toxins. The organism also produces a dermonecrotic toxin (DNT) that stimulates osteoclastic bone resorption and contributes to turbinate atrophy in swine but is less significant in dogs and cats. The ability to survive intracellularly within macrophages and epithelial cells allows B. bronchiseptica to evade host immune clearance and establish persistent infection.

Diagnostic Approaches

Sample Collection

For optimal recovery of B. bronchiseptica, samples should be collected from the nasopharynx, oropharynx, or trachea using sterile swabs. Transtracheal wash or bronchoalveolar lavage (BAL) is preferred in cases of lower respiratory tract involvement. Samples should be placed in transport medium (e.g., Amies with charcoal) and processed within 24 hours.

Culture and Isolation

B. bronchiseptica grows on MacConkey agar and Bordet-Gengou agar, producing small, convex, grayish colonies after 48 hours of aerobic incubation at 35-37 degrees Celsius. The organism is oxidase-positive, catalase-positive, and urease-positive. Culture remains the gold standard for diagnosis but has limited sensitivity in chronically infected or antibiotic-treated animals.

Molecular Detection

Polymerase chain reaction (PCR) assays targeting the fla gene or the Bordetella virulence genes offer higher sensitivity and specificity compared to culture. Real-time PCR can detect B. bronchiseptica in mixed infections and is particularly useful for rapid diagnosis in shelter and kennel settings. Multiplex PCR panels that include other respiratory pathogens (e.g., canine parainfluenza virus, canine adenovirus type 2, feline herpesvirus-1, feline calicivirus) are commercially available and recommended for comprehensive evaluation of CIRDC and feline URTIs.

Serology

Serological testing (e.g., ELISA) is not routinely used for diagnosis of acute infection due to the prevalence of antibodies in vaccinated or previously exposed animals. However, paired serology may be useful in epidemiological studies.

Antimicrobial Susceptibility Testing

Given the emergence of antimicrobial resistance, susceptibility testing is recommended for isolates from refractory cases. Khalifa et al. [5] documented high beta-lactam resistance in Gram-negative bacteria associated with kennel cough and cat flu in Egypt, including B. bronchiseptica isolates resistant to ampicillin, amoxicillin-clavulanate, and cephalosporins. Resistance to tetracyclines and fluoroquinolones has also been reported. Therefore, empirical antimicrobial therapy should be guided by local resistance patterns and ideally confirmed by culture and sensitivity.

Treatment

Antimicrobial Therapy

The primary goal of antimicrobial therapy is to reduce bacterial shedding and prevent secondary pneumonia. Doxycycline (5-10 mg/kg PO q12h for 10-14 days) is considered the first-line agent for both dogs and cats due to its efficacy against B. bronchiseptica and good tissue penetration. Alternative agents include fluoroquinolones (e.g., enrofloxacin, marbofloxacin) and potentiated sulfonamides. Beta-lactam antibiotics (e.g., amoxicillin-clavulanate) may be effective against susceptible strains, but resistance is increasingly documented [5]. Treatment should be continued for at least 48 hours beyond clinical resolution.

Supportive Care

Supportive care includes cough suppressants (e.g., butorphanol, hydrocodone) for non-productive cough in dogs, although their use is controversial in productive cough. Nebulization with saline and bronchodilators (e.g., terbutaline) may aid in clearing respiratory secretions. In severe cases, oxygen therapy and fluid support are indicated.

Prognosis

Uncomplicated cases of kennel cough in dogs typically resolve within 1-3 weeks. Feline bordetellosis carries a guarded prognosis in kittens and immunocompromised cats, with mortality rates up to 10% in severe outbreaks.

Control and Prevention

Vaccination

Vaccination is a cornerstone of kennel cough prevention in dogs. Modified-live intranasal vaccines containing B. bronchiseptica (often combined with canine parainfluenza virus and canine adenovirus type 2) induce mucosal immunity and provide rapid protection within 72 hours. Injectable bacterins are also available but are less effective at preventing colonization. Appel [6] reviewed forty years of canine vaccination and noted that intranasal B. bronchiseptica vaccines significantly reduce the incidence and severity of kennel cough in high-risk populations. In cats, intranasal vaccines against B. bronchiseptica are available in some regions and are recommended for cats in multi-cat environments or shelters.

Biosecurity and Management

Control measures include isolation of affected animals, adequate ventilation, disinfection of contaminated surfaces with quaternary ammonium compounds or bleach (1:32 dilution), and reduction of stress. In shelter settings, cohorting and all-in/all-out management strategies help limit spread. Foley et al. [4] emphasized that overcrowding and poor air quality are major risk factors for feline bordetellosis.

Zoonotic Considerations

B. bronchiseptica is a rare zoonotic pathogen, primarily affecting immunocompromised individuals such as cystic fibrosis patients and transplant recipients [3, 7]. Moore et al. [3] highlighted the risk of zoonotic infection from live bacterial veterinary vaccines, particularly for cystic fibrosis patients. Veterinary personnel and owners of infected pets should be informed of this risk, and appropriate hygiene measures should be implemented.

Novel Control Strategies

Bacteriophage therapy represents an emerging approach for controlling B. bronchiseptica infections. Petrovic et al. [8] isolated the first Siphoviridae family bacteriophages infecting B. bronchiseptica from environmental samples. These phages demonstrated lytic activity and may offer a targeted alternative to antibiotics, particularly in the context of rising antimicrobial resistance.

Diagnostic Decision Tree

The following Mermaid diagram outlines a diagnostic algorithm for suspected B. bronchiseptica infection in dogs and cats presenting with respiratory signs.

flowchart TD
    A[Patient presents with respiratory signs], > B{History of kennel/shelter exposure?}
    B, >|Yes| C[Collect nasopharyngeal or tracheal swab]
    B, >|No| D[Consider other causes: viral, allergic, parasitic]
    C, > E[Perform real-time PCR for Bordetella bronchiseptica]
    E, > F{Result positive?}
    F, >|Yes| G[Initiate doxycycline therapy]
    F, >|No| H[Perform culture and susceptibility testing]
    H, > I{Isolate B. bronchiseptica?}
    I, >|Yes| G
    I, >|No| J[Re-evaluate for other pathogens]
    G, > K[Monitor clinical response]
    K, > L{Improvement in 48-72 hours?}
    L, >|Yes| M[Complete 10-14 day course]
    L, >|No| N[Re-culture and adjust antibiotics based on susceptibility]

Summary Table of Key Diagnostic Methods

Conclusion

Bordetella bronchiseptica remains a significant bacterial pathogen in the etiology of kennel cough in dogs and feline upper respiratory tract infections. Accurate diagnosis relies on molecular methods such as PCR, complemented by culture and susceptibility testing in the face of rising antimicrobial resistance [5]. Control strategies should emphasize vaccination, biosecurity, and prudent antimicrobial use. Emerging therapies, including bacteriophages [8], may offer future alternatives. Veterinary practitioners must remain vigilant to the zoonotic potential of this organism, particularly in households with immunocompromised individuals [3, 7].

References

[1] Garbal M, Adaszek L, Lyp P, et al. Occurrence of Bordetella bronchiseptica in domestic cats with upper respiratory tract infections. Pol J Vet Sci. 2016;19(3):563-567. https://pubmed.ncbi.nlm.nih.gov/27487509/

[2] Khayer B, Magyar T, Wehmann E. Flagellin typing of Bordetella bronchiseptica strains originating from different host species. Vet Microbiol. 2014;174(3-4):558-562. https://pubmed.ncbi.nlm.nih.gov/25153650/

[3] Moore JE, Rendall JC, Millar BC. A doggy tale: Risk of zoonotic infection with Bordetella bronchiseptica for cystic fibrosis (CF) patients from live licenced bacterial veterinary vaccines for cats and dogs. J Clin Pharm Ther. 2022;47(1):1-4. https://pubmed.ncbi.nlm.nih.gov/34328230/

[4] Foley JE, Rand C, Bannasch MJ, et al. Molecular epidemiology of feline bordetellosis in two animal shelters in California, USA. Prev Vet Med. 2002;54(2):141-156. https://pubmed.ncbi.nlm.nih.gov/12069777/

[5] Khalifa HO, Oreiby AF, Okanda T, et al. High beta-lactam resistance in Gram-negative bacteria associated with kennel cough and cat flu in Egypt. Sci Rep. 2021;11(1):3355. https://pubmed.ncbi.nlm.nih.gov/33558604/

[6] Appel MJ. Forty years of canine vaccination. Adv Vet Med. 1999;41:309-324. https://pubmed.ncbi.nlm.nih.gov/9890024/

[7] Ner Z, Ross LA, Horn MV, et al. Bordetella bronchiseptica infection in pediatric lung transplant recipients. Pediatr Transplant. 2003;7(5):413-417. https://pubmed.ncbi.nlm.nih.gov/14738306/

[8] Petrovic A, Kostanjsek R, Rakhely G, et al. The first Siphoviridae family bacteriophages infecting Bordetella bronchiseptica isolated from environment. Microb Ecol. 2017;73(2):368-377. https://pubmed.ncbi.nlm.nih.gov/27628741/